Home » Topics » BioWorld

BioWorld
RSS

CANADA APPROVE IMMUNOMEDICS TRIALS

Jan. 15, 1992

ROBERTS TO BUY TRIALS MANAGEMENT COMPANY

Jan. 15, 1992

CYTRX FILES IND FOR BURN TREATMENT

Jan. 15, 1992

ONCOSCINT APPROVED IN ITALY

Jan. 15, 1992

ELAN AGREES TO ACQUIRE VEGA

Jan. 15, 1992

ALPHA-BETA BEGINS FIRST TRIALS

Jan. 15, 1992

ENZO STOCK CONTINUES TO RISE

Jan. 15, 1992

ZYNAXIS FILES FOR 2 MILLION-SHARE IP0

Jan. 15, 1992

START-UP FOCUSES ON TRANSCRIPTION FACTORS

Jan. 15, 1992

NIH CONTRACTS WITH MORE LAW FIRMS

Jan. 14, 1992

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...